29442-43-1

Upstream product

• 111-24-0 1,5-dibromo-pentane 
• 98-13-5 Phenyltrichlorosilane 
• 2406-34-0 1,1-dichloro-1-silacyclohexane 
• 108-90-7 chlorobenzene 
• 85125-33-3 1-phenyl-1-silacyclohexane 
• 23708-48-7 pentamethylenebis(magnesium bromide) 

Downstream Products

• 18753-43-0 1,1'-diphenyl-1,1'bi(silacyclohexyl) 
• 85125-33-3 1-phenyl-1-silacyclohexane 
• 18753-38-3 (1,1'-phenyl-1,1'-silacyclohex-1-yl)disiloxane 

Relevant academic research and scientific papers

1-t-Butyl-1-phenyl-1-silacyclohexane: Synthesis, conformational analysis in gas and solution by GED, FT-IR and theoretical calculations

1-t-Butyl-1-phenyl-1-silacyclohexane 1, the first disubstituted silacyclohexane with the most bulky substituent, t-Bu group, at silicon, was synthesized via the sequence of reactions PhSiCl3 → Ph(Cl)Si(CH2)5 → Ph(t-Bu)Si(C

1-Methylthio-1-phenyl-1-silacyclohexane: Synthesis, conformational preferences in gas and solution by GED, NMR and theoretical calculations

1-Methylthio-1-phenyl-1-silacyclohexane 1, the first silacyclohexane with the sulfur atom at silicon, was synthesized and its molecular structure and conformational preferences studied by gas-phase electron diffraction (GED) and low temperature 13C and 29Si NMR spectroscopy (LT NMR). Quantum-chemical calculations were carried out both for the isolated species and solvate complexes in gas and in polar medium. The predominance of the 1-MeSaxPheq conformer in gas phase (1-Pheq:1-Phax = 55:45, ΔG° = 0.13 kcal/mol) determined from GED is consistent with that measured in the freon solution by LT NMR (1-Pheq:1-Phax = 65:35, ΔG° = 0.12 kcal/mol), the experimentally measured ratios being close to that estimated by quantum chemical calculations at both the DFT and MP2 levels of theory.

Entecavir intermediate and its preparation method

The invention discloses an entecavir intermediate and a preparation method thereof. A provided preparation method for an entecavir intermediate compound 8 comprises the following steps: performing hydroxyl protection group removal reaction on a compound 9 in a solvent under an acidic condition, so as to obtain the compound 8. A provided preparation method for an entecavir intermediate compound 9 comprises the following steps: performing hydroxyl protection group adding reaction on a compound 10 in an aprotic organic solvent under an alkali condition, so as to obtain the compound 9. The preparation methods are cheap and easily available in raw materials, mild in reaction conditions, relatively high in product yield, good in atom economy, friendly to environment, and suitable for industrialized production.

A kind of preparation method of the midbody of entecavir, and intermediate

The invention discloses Entecavir intermediates and a preparation method thereof. The preparation method of an Entecavir intermediate represented by a formula IV or IV' shown in descriptions comprises the following step of enabling a compound V to be subjected to amino protecting group and hydroxyl protecting group removal reaction in the presence of protonic acid in a solvent. The preparation method disclosed by the invention has the advantages that raw materials are cheap and are easily obtained, reaction conditions are mild, side reactions are few, the yield is high, the pollution to the environment is little, and the intermediates are easily purified and separated, so that the preparation method is applicable to industrial production.

Entecavir intermediate and its preparation method

The invention discloses an entecavir intermediate and a preparation method thereof. A provided preparation method for an entecavir intermediate compound 10 comprises the following steps: performing reducing reaction on an ester compound 11 in an organic solvent under the effect of a reducing agent, so as to obtain the compound 10. A provided preparation method for an entecavir intermediate compound 11 comprises the following steps: reacting a compound 12 with a hydroxyl protection reagent in an organic solvent in the presence of an acid to add a hydroxyl protection group, so as to obtain the compound 11. The preparation methods are cheap and easily available in raw materials, mild in reaction conditions, relatively high in product yield, good in atom economy, friendly to environment, and suitable for industrialized production.

Entecavir intermediate and its preparation method

The invention discloses an entecavir intermediate and a preparation method thereof. A provided preparation method for an entecavir intermediate compound 3 comprises the following steps: performing reducing reaction on a compound 4 in a solvent, so as to obtain the compound 3. A provided preparation method for an entecavir intermediate compound 4 comprises the following steps: performing transacetalation reaction on a compound 5 and a compound 18 in an organic solvent under an acid condition, so as to obtain the compound 4. The preparation methods are cheap and easily available in raw materials, mild in reaction conditions, relatively high in product yield, good in atom economy, friendly to environment, and suitable for industrialized production.

A kind of preparation method of the midbody of entecavir, and intermediate

The invention discloses Entecavir intermediates and a preparation method thereof. The preparation method of an Entecavir intermediate represented by a formula VIII shown in descriptions comprises the following step of enabling compounds IX and VIII' to be subjected to ring cleavage reaction in the presence of alkali in a non-aprotic organic solvent. The invention further discloses an Entecavir intermediate compound represented by a formula X or IX shown in descriptions. The preparation method disclosed by the invention has the advantages that raw materials are cheap and are easily obtained, the reaction conditions are mild, side reactions are few, the yield is high, the pollution to the environment is little, and the intermediates are easily purified and separated, so that the preparation method is applicable to industrial production.

1-Phenyl-1-halo-1-silacyclohexanes

The approaches to synthesis of 1-phenyl-1-halo-1-silacyclohexanes C5H10Si(Ph)X (X = F, Cl, Br) have been examined. 1-Phenyl-1-chloro-1-silacyclohexane has been prepared via the known reaction of phenyltrichlorosilane with dimagnesium

Conformational preferences of Si-Ph,H and Si-Ph,Me silacyclohexanes and 1,3-thiasilacyclohexanes. Additivity of conformational energies in 1,1-disubstituted heterocyclohexanes

The conformational equilibria of 1-phenyl-1-silacyclohexane 1, 3-phenyl-1,3-thiasilacyclohexane 2, 1-methyl-1-phenyl-1-silacyclohexane 3, and 3-methyl-3-phenyl-1,3-thiasilacyclohexane 4 have been studied for the first time by low temperature 13

Silacycloalkane amides

Anti-atherosclerotic agents of the formula: STR1 wherein R1 is (a) alkyl having from 1 to 22 carbon atoms; or (b) of the formula STR2 in which m is 0, 1 or 2, and each of R' and R" is, independently, hydrogen, halo or lower alkyl or alkoxy; R2 and R3 are joined to form with the silicon atom a heterocyclic ring having from 3 to 20 ring members; and R is an aralkyl-, phenyl- tryptophanyl- or benzocycloalkyl-type radical, eg 1-butyl-N-[(2-(4'-methyl-phenyl)-1-phenylethyl]-1-silacyclohexane propanamide, are obtained by reducing corresponding α,β-unsaturated analogs.